Medartha Capital Fund — MedArtha Capital | wisefolio

Medartha Capital Fund

Operators once, Now thoughtful investors

IN/AIF2/25-26/2021Cat II

Private equity, private credit and real-estate funds that don't employ leverage except for operating needs. The largest AIF category.

Overview

About

MedArtha Capital Fund is a SEBI-registered Category II Alternative Investment Fund (IN/AIF2/25-26/2021), registered on January 19, 2026, and managed by MedArtha Capital Advisors Private Limited. The fund is headquartered at 28th Floor, Unit No. 2801, Building No. 4, Maxima, JVLR Road, Jogeshwari, Mumbai 400060. MedArtha Capital is India's first dedicated investment platform focused exclusively on the medical devices and digital health sectors. The fund was launched by Ganesh P. Sabat, former CEO of Sahajanand Medical Technologies (SMT), a leading cardiac stent manufacturer. With 15 years of experience in corporate strategy and finance across medical devices, life sciences, chemicals, and financial services, Sabat launched MedArtha in late 2025. The fund announced a partnership with the Andhra Pradesh MedTech Zone (AMTZ) for a dedicated MedTech Capital Fund, inaugurated in Mumbai by Union Minister Piyush Goyal in March 2026. The fund targets a corpus of ₹1,000 crore, with the government of India potentially contributing approximately ₹500 crore through the Research, Development and Innovation (RDI) scheme. MedArtha plans to invest in 10–12 high-growth medtech companies with revenues of ₹30–80 crore, deploying capital over 2–3 years within an 8-year fund lifecycle. The fund focuses on companies developing advanced medical devices including MRI machines, CT scanners, cathlab systems, and neurovascular equipment — to reduce India's heavy import dependency in these segments.

Investment Philosophy

MedArtha Capital operates as an operator-led investment platform, combining financial investment with deep operational expertise in the medical devices sector. The fund backs small and mid-size medtech companies with established products that require capital and operational support to scale manufacturing and expand into larger markets. The investment approach bridges the financing gap in India's medtech ecosystem while advancing the 'Make in India' agenda in strategic healthcare sectors.

Team— 1

Ganesh P. Sabat

Founder & Managing Partner

Former CEO of Sahajanand Medical Technologies (SMT), India's leading cardiac stent manufacturer, where he served from 2013 to 2025. MBA from Washington University in St. Louis and a Company Secretary from ICSI. Has 15 years of experience in corporate strategy and finance across medical devices, life sciences, chemical, and financial services industries. Founded MedArtha Capital in late 2025 to bridge the funding and operational gap in India's medtech ecosystem. The SEBI-registered contact for Medartha Capital Fund.

Registration

SEBI Registration

SEBI-registered

Reg. NumberIN/AIF2/25-26/2021

VintageJan 2026

Valid ToPerpetual

Contact PersonGanesh Sabat

Address28th Floor, Unit No. 2801, Building No. 4, Maxima, JVLR Road, CTS NO 1 B of Village Majas, Jogeshwari, Mumbai, Maharashtra, 400060

Insights

No insights published yet.

Disclaimer

Investments in AIFs carry market and credit risk including possible loss of capital. Past performance does not indicate future returns. Information shown is sourced from the issuer's PPM and SEBI filings — confirm against the latest PPM before committing. wisefolio is an information platform; it is not registered with SEBI as an investment adviser, portfolio manager, or distributor. By using this page you accept our terms and privacy policy, including the self-attestation that you are eligible to view AIF marketing material under SEBI rules.